Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Minoo Ahmadinejad Explores Emicizumab
Dec 13, 2025, 15:51

Minoo Ahmadinejad Explores Emicizumab

Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:

”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.

Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.

Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.

The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.

Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”

Minoo Ahmadinejad Explores Emicizumab

Stay updated with Hemostasis Today.

aPTT bleeding disorders Emicizumab Health Hematology Hemophilia Hemostasis Hemostasis Today Medicine Minoo Ahmadinejad
NewsFeed